United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lucozade ribena suntory ltd - not applicable

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lucozade ribena suntory ltd - not applicable

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lucozade ribena suntory ltd - oral solution

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - ascorbic acid 0.003%; caffeine 0.019%; glucose monohydrate 17.3%;   - oral solution - active: ascorbic acid 0.003% caffeine 0.019% glucose monohydrate 17.3%  

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - citric acid 12.77 mg/g; macrogol 3350 755.68 mg/g (as macrogol 3350 prepared solution contains 6% w/w); potassium chloride 10.55 mg/g; sodium chloride 37.33 mg/g;  ; sodium sulfate 80.62 mg/g; citric acid 771.868 mg/g; heavy magnesium oxide 225.128 mg/g; sodium picosulfate 0.64 mg/g - combination - active: citric acid 12.77 mg/g macrogol 3350 755.68 mg/g (as macrogol 3350 prepared solution contains 6% w/w) potassium chloride 10.55 mg/g sodium chloride 37.33 mg/g   sodium sulfate 80.62 mg/g excipient: ascorbic acid aspartame lemon flavour ql58817 active: citric acid 771.868 mg/g heavy magnesium oxide 225.128 mg/g sodium picosulfate 0.64 mg/g excipient: aspartame - indicated for bowel emptying and cleansing by means of total gastrointestinal tract perfusion in preparation for gastrointestinal examination

United States - English - NLM (National Library of Medicine)

dentsply llc. professional division trading as "dentsply professional" - chlorhexidine gluconate (unii: mor84mud8e) (chlorhexidine - unii:r4ko0dy52l) - chlorhexidine gluconate 1.2 mg in 1 ml - chlorhexidine gluconate oral rinse should not be used by persons who are known to be hypersensitive to chlorhexidine gluconate or other formula ingredients.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - chlorhexidine gluconate (unii: mor84mud8e) (chlorhexidine - unii:r4ko0dy52l) - chlorhexidine gluconate 1.2 mg in 1 ml - chlorhexidine gluconate oral rinse, 0.12% should not be used by persons who are known to be hypersensitive to chlorhexidine gluconate or other formula ingredients.

United States - English - NLM (National Library of Medicine)

cardinal health - chlorhexidine gluconate (unii: mor84mud8e) (chlorhexidine - unii:r4ko0dy52l) - chlorhexidine gluconate 1.2 mg in 1 ml - chlorhexidine gluconate oral rinse, 0.12% should not be used by persons who are known to be hypersensitive to chlorhexidine gluconate or other formula ingredients.

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - quinidine gluconate (unii: r6875n380f) (quinidine - unii:itx08688jl) - quinidine gluconate 324 mg - conversion of atrial fibrillation/flutter in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine gluconate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine gluconate does not restore sinus rhythm within a reasonable time (see dosage and administration ), then quinidine gluconate should be discontinued. reduction of frequency of relapse into atrial fibrillation/flutter chronic therapy with quinidine gluconate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine gluconate. the increased risk of death should specifically be considered. quinidine gluconate should be used only after alternative meas

United States - English - NLM (National Library of Medicine)

richmond pharmaceuticals, inc. - quinidine gluconate (unii: r6875n380f) (quinidine - unii:itx08688jl) - quinidine gluconate 324 mg - conversion of atrial fibrillation/flutter in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine gluconate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine gluconate does not restore sinus rhythm within a reasonable time (see dosage and administration ), then quinidine gluconate should be discontinued. reduction of frequency of relapse into atrial fibrillation/flutter chronic therapy with quinidine gluconate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine gluconate. the increased risk of death should specifically be considered. quinidine gluconate should be used only after alternative meas